Michael Koklas

Van Berkom & Associates, Inc. (Van Berkom) is a specialized investment management firm headquartered in Montreal, Canada. The firm was founded by J. Sebastian van Berkom in 1991 and is owned by JSVB Investments, Inc. They manage stock portfolios for large North American pension funds, corporations, foundations, and endowment funds. Van Berkom is a signatory to the UN Principles for Responsible Investment (UNPRI).

Deloitte Corporate Finance, Inc. provides financial, accounting, tax, and other business services. The company also offers audit, financial advisory, and consulting services through locations across the country. It is located in Toronto, Canada.

CN Investment Division (the Division) is an investment management firm headquartered in Montreal, Quebec. The firm was founded in 1968 and is owned by Canadian National Railway Co. (CNR) (NYSE: CNI; TSE: CNR). CNID manages the pension fund of CNR. The Division also manages the assets of the CN Pension Plan for Senior Management and the BC Rail Pension Plan.

Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada.

Ski Québec Alpin Federation operates as non-profit sports organization. The company was founded in 1967 and is headquartered in Montréal, Canada.

Alpine Canada Alpin, Inc. operates as national governing body for alpine, para-alpine and ski cross racing in Canada. The company was founded in 1956 and is headquartered in Calgary, Canada.

Tactex Asset Management, Inc. (Tactex) is a Canadian wealth management firm headquartered in Montréal, Quebec. The firm was founded in 2011 and is a subsidiary of Mylo Financial Technologies, Inc., which is owned by Mogo, Inc. (NASDAQ; TSX: MOGO). Tactex provides discretionary portfolio management services designed for Canadian investors who seeks to achieve long-term investment goals. The firm’s services also include facilitating transactions with qualifying Canadian investors in the prospectus exempt market and establishing cost effective investment funds for institutional clients.

Axium Infrastructure, Inc. (Canada) (Axium Infrastructure) is a private equity firm founded in 2009 by Pierre Anctil. The firm is headquartered in Toronto with additional office in New York.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada.

Sectoral Asset Management Inc (Private Equity) (Sectoral Asset Management) is a private equity subsidiary of Sectoral Asset Management, Inc. founded in 2008 by Michael Sjöström. The firm is headquartered in Montréal, Quebec.

Stifel Nicolaus Canada, Inc. (Stifel Canada) is a Canadian broker-dealer subsidiary of Stifel Financial Corp. (NYSE: SF) in the US. Headquartered in Toronto, Stifel Canada provides institutional sales and trading to corporate clients and institutional investors. The firm also offers a much broader suite of products and services, while remaining the same group of dedicated professionals serving Canadian capital markets.

Saisei Ventures LLC (Saisei Ventures) is a venture capital firm founded by Jonathan Yeh in 2020. The firm is headquartered in Cambridge, Massachusetts.

Ryne Biotechnology, Inc. is an American US-based biotechnology company that focuses on developing next-generation approaches to cure neurological disorders. The company utilizes induced pluripotent stem cell (iPSC) technology to advance its off-the-shelf neuron replacement therapeutics. Ryne Bio is dedicated to advancing a pipeline targeting neurological diseases by focusing on an iPSC technology platform and forging partnerships with leaders in surgical delivery and clinical development.